Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab®-Paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First Line Treatment in Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer

NCT01881230 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT01881230
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01881230 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab®-Paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First Line Treatment in Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer
Lead sponsor
Celgene
Phase
Phase 2/3
Overall status
Completed
Start date
September 26, 2013
Completion date
October 28, 2016
Enrollment
191 (actual)
Sites
140

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast tumor, cancer of the breast, estrogen receptor- negative breast cancer, her2- negative breast cancer, metastatic breast cancer, progesterone receptor- negative breast cancer, recurrent breast cancer, stage iv breast cancer, triple-negative breast cancer, triple-negative metastatic breast cancer